936250-21-4

Basic information

• Product Name: 4-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester;2-(4-BOC-piperazino)pyridine-4-boronic acid,pinacol ester;2-[4-(tert-Butoxycarbonyl)piperazin-1-yl]-4-(4,4,5,5-tetramethyl,1,3,2-dioxaborolan-2-yl)pyridine;2-(4-tert-Butoxycarbonylpiperazin-1-yl)pyridine-4-boronic acid;tert-butyl 4-(4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine-1-carboxylate
• CAS NO: 936250-21-4
• Molecular Formula: C₂₀H₃₂BN₃O₄
• Molecular Weight: 389.29678
• Mol File: 936250-21-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 523.2°C at 760 mmHg
• Flash Point: 270.2°C
• Appearance: /
• Density: 1.14g/cm³
• Vapor Pressure: 4.82E-11mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: 2-8°C
• PKA: 7.58±0.29(Predicted)
• CAS DataBase Reference: 4-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester(936250-21-4)
• EPA Substance Registry System: 4-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester(936250-21-4)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• Hazardous Substances Data: 936250-21-4(Hazardous Substances Data)

Usage

General Description

The chemical "4-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester" is a complex compound containing several functional groups. It includes a piperazine ring, a carboxylic acid group, and a tert-butyl ester group. Additionally, it incorporates a boron-containing heterocycle, specifically a dioxaborolane ring. This chemical may have potential applications in medicinal and pharmaceutical research, due to its intricate structure and potential for interacting with biological systems. Further analysis and research are necessary to fully understand its properties and potential uses.

InChI:InChI=1/C20H32BN3O4/c1-18(2,3)26-17(25)24-12-10-23(11-13-24)16-14-15(8-9-22-16)21-27-19(4,5)20(6,7)28-21/h8-9,14H,10-13H2,1-7H3

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 58530-53-3 2,4-dibromopyridine 
• 1197294-80-6 tert-butyl 4-(4-bromopyridin-2-yl)piperazine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 957198-31-1 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-yl)piperazine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Relevant articles and documents

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors

N-Myristoyltransferase (NMT) represents a promising drug target within the parasitic protozoa Trypanosoma brucei (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness. We have previously validated T. brucei NMT as a promising druggable target for the treatment of HAT in both stages 1 and 2 of the disease. We report on the use of the previously reported DDD85646 (1) as a starting point for the design of a class of potent, brain penetrant inhibitors of T. brucei NMT.

ALKYNYL COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.